カテゴリ： Allied Market Research, 世界, 医療/バイオ

坐骨神経痛治療のグローバル市場（2021～2031）：急性坐骨神経痛、慢性坐骨神経痛、その他

■ 英語タイトル：Sciatica Treatment Market By Type (Acute sciatica, Chronic sciatica, Others), By Drug class (Non-steroidal anti-inflammatory drugs, Steroids, Antidepressants, Others), By Distribution channel (Hospital pharmacies, Retail and specialty pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23MC088）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23MC088
■ 発行日：2023年1月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：241
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[坐骨神経痛治療のグローバル市場（2021～2031）：急性坐骨神経痛、慢性坐骨神経痛、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の調査資料では、2021年には678.02百万ドルであった世界の坐骨神経痛治療市場規模が2031年には991.26百万ドルへ及び、2022年から2031年の間にCAGR 3.9％増加すると推測されています。本調査資料では、坐骨神経痛治療の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場概要、種類別（急性坐骨神経痛、慢性坐骨神経痛、その他）分析、薬剤クラス別（非ステロイド性抗炎症薬、ステロイド、抗うつ薬、その他）分析、流通チャネル別（病院内薬局、小売・専門薬局、オンラインプロバイダー）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）分析、競争状況、企業情報などを整理しました。並びに、本資料に記載されている企業として、Abbott Laboratories、Teva Pharmaceutical Industries Limited、Aurobindo Pharma、Sorrento Therapeutics, Inc、Alkem Laboratories Ltd、Amneal Pharmaceuticals LLC、Johnson and Johnson、Sun Pharmaceutical Industries Ltd.、Sinfonia Biotherapeutics、Zydus Lifesciences Limitedなどが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の坐骨神経痛治療市場規模：種類別
- 急性坐骨神経痛治療の市場規模
- 慢性坐骨神経痛治療の市場規模
- その他坐骨神経痛治療の市場規模
・世界の坐骨神経痛治療市場規模：薬剤クラス別
- 非ステロイド性抗炎症薬の市場規模
- ステロイドの市場規模
- 抗うつ薬の市場規模
- その他坐骨神経痛治療の市場規模
・世界の坐骨神経痛治療市場規模：流通チャネル別
- 病院内薬局チャネルの市場規模
- 小売・専門薬局チャネルの市場規模
- オンラインプロバイダーチャネルの市場規模
・世界の坐骨神経痛治療市場規模：地域別
- 北米の坐骨神経痛治療市場規模
- ヨーロッパの坐骨神経痛治療市場規模
- アジア太平洋の坐骨神経痛治療市場規模
- 中南米/中東・アフリカの坐骨神経痛治療市場規模
・競争状況
・企業情報

坐骨神経痛治療の市場規模は、2021年に6億7,802万ドルと評価され、2022年から2031年まで年平均成長率3.9%で成長して2031年には9億9,126万ドルに達すると予測されています。

坐骨神経痛は、主に坐骨神経に影響を及ぼす痛みを指しますが、坐骨神経とは、腰から臀部、両足を通る神経のことです。坐骨神経痛は通常、下半身の片側だけに起こりますが、腰から臀部、太ももの裏側、ふくらはぎに至る神経経路のどの部分にも痛みが起こる可能性があります。さらに、坐骨神経痛の一般的な症状としては、座ると悪化する脚の痛み、脚の灼熱感やしびれ、立っているのが困難になるような痛みなどがあります。また、坐骨神経のどの部分が痛むかによって、足や足の指が痛むこともあります。坐骨神経痛は、様々な薬や鎮痛剤を用いて治療することができます。薬には、抗炎症薬、鎮痛薬、抗けいれん薬などがあります。

坐骨神経痛治療市場の成長を促進する主な要因としては、坐骨神経痛の発生率の増加、坐骨神経痛の新規治療薬を開発するための研究開発活動の急増、坐骨神経痛とその治療法に関する人々の意識の高まりなどが挙げられます。発展途上国や先進国では、坐骨神経痛の発生率が増加しています。坐骨神経痛の主な原因は、椎間板ヘルニアやすべり症、椎間板変性症、脊柱管狭窄症、脊椎すべり症などです。ジョンズ・ホプキンス関節炎センターによると、最近の人口推計では、米国における強直性脊椎炎（AS）の有病率は約0.2～0.5％で、複数の国のデータに基づくと、強直性脊椎炎（AS）の年齢・性別調整後の発症率は人口10万人あたり0.4～14人です。

また、1年間に約2％の人が椎間板ヘルニアになると言われています。椎間板ヘルニアが腰の椎骨に起こると、坐骨神経を圧迫して坐骨神経痛を引き起こします。このように、椎間板ヘルニアの罹患率は非常に高く、坐骨神経痛の発生率は増加しています。これが坐骨神経痛治療市場の成長を後押ししています。

さらに、製薬分野での研究開発活動の増加が市場の成長を促進しています。大手企業は、坐骨神経痛の治療に応用できる、強力で効率的な新薬やAPIの開発に注力しています。さらに、製薬会社による学術機関や民間の受託研究機関（CRO）への研究活動のアウトソーシングが増加しており、これにより、企業はますます高度化する技術の世界で競争力と柔軟性を維持することができます。このことが、坐骨神経痛やその他の疾患に対する新しい薬物療法を開発する主要な市場プレイヤーをサポートし、市場の成長をさらに後押ししています。

様々な主要因が市場の成長を促進していますが、坐骨神経痛に対する特定の治療法が承認されていないことや、代替治療法の存在など、市場の成長を阻害する要因もあります。理学療法や装具、外科的治療などの代替治療オプションが坐骨神経痛治療市場の成長を制限しています。しかし、アジア太平洋やLAMEAの新興国は、市場プレーヤーに有利な投資機会を提供しています。例えば、中国やインドのように人口が多く、患者数が多い国は、市場成長にとって有利な機会を提供します。

坐骨神経痛治療市場は、種類、治療法、流通チャネル、地域によって区分されます。種類別では、急性坐骨神経痛、慢性坐骨神経痛、その他に分類されます。薬剤クラス別では、非ステロイド性抗炎症薬（NSAIDs）、ステロイド、抗うつ薬、その他に分類されます。販売チャネル別では、病院薬局、小売薬局、専門薬局、オンラインプロバイダーに分類されます。 地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他の欧州地域）、アジア太平洋地域（日本、中国、オーストラリア、インド、韓国、その他のアジア太平洋地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他のLAMEA地域）に市場を分けて分析しています。

坐骨神経痛治療市場の主要企業には、Alkem Laboratories Limited、Amneal Pharmaceuticals LLC、Aurobindo Pharma、Johnson & Johnson、Sinfonia Biotherapeutics、Sorrento Therapeutics, Inc、Sun Pharmaceutical Industries Ltd.、Teva Pharmaceutical Industries Limited、Zydus Groupなどがあります。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの坐骨神経痛治療市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、坐骨神経痛治療の市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・坐骨神経痛治療市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・坐骨神経痛治療の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
種類別
急性坐骨神経痛
慢性坐骨神経痛
その他

薬剤クラス別
非ステロイド性抗炎症薬
ステロイド剤
抗うつ薬
その他

流通チャネル別
病院薬局
小売・専門薬局
オンラインプロバイダー

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Abbott Laboratories
Teva Pharmaceutical Industries Limited
Aurobindo Pharma
Sorrento Therapeutics, Inc
Alkem Laboratories Ltd
Amneal Pharmaceuticals LLC
Johnson and Johnson
Sun Pharmaceutical Industries Ltd.
Sinfonia Biotherapeutics
Zydus Lifesciences Limited

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Moderate threat of substitutes
3.3.4. Moderate threat of new entrants
3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in incidence of sciatica
3.4.1.2. Increase in geriatric population
3.4.1.3. Increase in R&D activities

3.4.2. Restraints
3.4.2.1. Presence of alternate treatment

3.4.3. Opportunities
3.4.3.1. Growth opportunity in emerging markets

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: SCIATICA TREATMENT MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Acute sciatica
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Chronic sciatica
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: SCIATICA TREATMENT MARKET, BY DRUG CLASS
5.1. Overview
5.1.1. Market size and forecast
5.2. Non-steroidal anti-inflammatory drugs
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Steroids
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Antidepressants
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Retail and specialty pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: SCIATICA TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Drug class
7.2.4. Market size and forecast, by Distribution channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Type
7.2.5.1.3. Market size and forecast, by Drug class
7.2.5.1.4. Market size and forecast, by Distribution channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Type
7.2.5.2.3. Market size and forecast, by Drug class
7.2.5.2.4. Market size and forecast, by Distribution channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Type
7.2.5.3.3. Market size and forecast, by Drug class
7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Drug class
7.3.4. Market size and forecast, by Distribution channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Type
7.3.5.1.3. Market size and forecast, by Drug class
7.3.5.1.4. Market size and forecast, by Distribution channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Type
7.3.5.2.3. Market size and forecast, by Drug class
7.3.5.2.4. Market size and forecast, by Distribution channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Type
7.3.5.3.3. Market size and forecast, by Drug class
7.3.5.3.4. Market size and forecast, by Distribution channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Type
7.3.5.4.3. Market size and forecast, by Drug class
7.3.5.4.4. Market size and forecast, by Distribution channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Type
7.3.5.5.3. Market size and forecast, by Drug class
7.3.5.5.4. Market size and forecast, by Distribution channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Type
7.3.5.6.3. Market size and forecast, by Drug class
7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Drug class
7.4.4. Market size and forecast, by Distribution channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Type
7.4.5.1.3. Market size and forecast, by Drug class
7.4.5.1.4. Market size and forecast, by Distribution channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Type
7.4.5.2.3. Market size and forecast, by Drug class
7.4.5.2.4. Market size and forecast, by Distribution channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Type
7.4.5.3.3. Market size and forecast, by Drug class
7.4.5.3.4. Market size and forecast, by Distribution channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Type
7.4.5.4.3. Market size and forecast, by Drug class
7.4.5.4.4. Market size and forecast, by Distribution channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Type
7.4.5.5.3. Market size and forecast, by Drug class
7.4.5.5.4. Market size and forecast, by Distribution channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Type
7.4.5.6.3. Market size and forecast, by Drug class
7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Drug class
7.5.4. Market size and forecast, by Distribution channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Type
7.5.5.1.3. Market size and forecast, by Drug class
7.5.5.1.4. Market size and forecast, by Distribution channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Type
7.5.5.2.3. Market size and forecast, by Drug class
7.5.5.2.4. Market size and forecast, by Distribution channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Type
7.5.5.3.3. Market size and forecast, by Drug class
7.5.5.3.4. Market size and forecast, by Distribution channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Type
7.5.5.4.3. Market size and forecast, by Drug class
7.5.5.4.4. Market size and forecast, by Distribution channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Abbott Laboratories
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Alkem Laboratories Ltd
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Amneal Pharmaceuticals LLC
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Johnson and Johnson
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Sinfonia Biotherapeutics
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Key strategic moves and developments
9.6. Sorrento Therapeutics, Inc
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Sun Pharmaceutical Industries Ltd.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Zydus Lifesciences Limited
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Teva Pharmaceutical Industries Limited
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Aurobindo Pharma
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 02. SCIATICA TREATMENT MARKET FOR ACUTE SCIATICA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 03. SCIATICA TREATMENT MARKET FOR CHRONIC SCIATICA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 04. SCIATICA TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 05. GLOBAL SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 06. SCIATICA TREATMENT MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 07. SCIATICA TREATMENT MARKET FOR STEROIDS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 08. SCIATICA TREATMENT MARKET FOR ANTIDEPRESSANTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 09. SCIATICA TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. GLOBAL SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 11. SCIATICA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. SCIATICA TREATMENT MARKET FOR RETAIL AND SPECIALTY PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. SCIATICA TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. SCIATICA TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 15. NORTH AMERICA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 16. NORTH AMERICA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 17. NORTH AMERICA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 18. NORTH AMERICA SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 19. U.S. SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 20. U.S. SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 21. U.S. SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 22. CANADA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 23. CANADA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 24. CANADA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 25. MEXICO SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 26. MEXICO SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 27. MEXICO SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 28. EUROPE SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 29. EUROPE SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 30. EUROPE SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 31. EUROPE SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 32. GERMANY SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 33. GERMANY SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 34. GERMANY SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 35. FRANCE SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 36. FRANCE SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 37. FRANCE SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 38. UK SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 39. UK SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 40. UK SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 41. ITALY SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 42. ITALY SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 43. ITALY SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 44. SPAIN SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 45. SPAIN SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 46. SPAIN SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 47. REST OF EUROPE SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 48. REST OF EUROPE SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 49. REST OF EUROPE SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 50. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 51. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 52. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 53. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 54. JAPAN SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 55. JAPAN SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 56. JAPAN SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 57. CHINA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 58. CHINA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 59. CHINA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 60. INDIA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 61. INDIA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 62. INDIA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 63. AUSTRALIA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 64. AUSTRALIA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 65. AUSTRALIA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 66. SOUTH KOREA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 67. SOUTH KOREA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 68. SOUTH KOREA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 69. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 70. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 71. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 72. LAMEA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 73. LAMEA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 74. LAMEA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 75. LAMEA SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 76. BRAZIL SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 77. BRAZIL SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 78. BRAZIL SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 79. SAUDI ARABIA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 80. SAUDI ARABIA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 81. SAUDI ARABIA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 82. SOUTH AFRICA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 83. SOUTH AFRICA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 84. SOUTH AFRICA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 85. REST OF LAMEA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 86. REST OF LAMEA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 87. REST OF LAMEA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 88. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 89. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 90. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 91. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 92. ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 93. ALKEM LABORATORIES LTD: KEY EXECUTIVES
TABLE 94. ALKEM LABORATORIES LTD: COMPANY SNAPSHOT
TABLE 95. ALKEM LABORATORIES LTD: PRODUCT SEGMENTS
TABLE 96. ALKEM LABORATORIES LTD: PRODUCT PORTFOLIO
TABLE 97. ALKEM LABORATORIES LTD: KEY STRATERGIES
TABLE 98. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
TABLE 99. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
TABLE 100. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
TABLE 101. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 102. JOHNSON AND JOHNSON: KEY EXECUTIVES
TABLE 103. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 104. JOHNSON AND JOHNSON: PRODUCT SEGMENTS
TABLE 105. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 106. SINFONIA BIOTHERAPEUTICS: KEY EXECUTIVES
TABLE 107. SINFONIA BIOTHERAPEUTICS: COMPANY SNAPSHOT
TABLE 108. SINFONIA BIOTHERAPEUTICS: PRODUCT SEGMENTS
TABLE 109. SINFONIA BIOTHERAPEUTICS: PRODUCT PORTFOLIO
TABLE 110. SINFONIA BIOTHERAPEUTICS: KEY STRATERGIES
TABLE 111. SORRENTO THERAPEUTICS, INC: KEY EXECUTIVES
TABLE 112. SORRENTO THERAPEUTICS, INC: COMPANY SNAPSHOT
TABLE 113. SORRENTO THERAPEUTICS, INC: PRODUCT SEGMENTS
TABLE 114. SORRENTO THERAPEUTICS, INC: PRODUCT PORTFOLIO
TABLE 115. SORRENTO THERAPEUTICS, INC: KEY STRATERGIES
TABLE 116. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 117. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 118. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 120. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 121. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
TABLE 122. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 123. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
TABLE 124. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 125. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 128. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 129. AUROBINDO PHARMA: KEY EXECUTIVES
TABLE 130. AUROBINDO PHARMA: COMPANY SNAPSHOT
TABLE 131. AUROBINDO PHARMA: PRODUCT SEGMENTS
TABLE 132. AUROBINDO PHARMA: PRODUCT PORTFOLIO

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 抗コクシジウム薬のグローバル市場（2021〜2031）：イオノフォア、合成薬
  • 治療薬物モニタリング（TDM）のグローバル市場（2021-2031）：消耗品、装置
  • 群発頭痛のグローバル市場（2021～2031）：反復発作性、慢性
  • 経口抗ウィルス薬のグローバル市場（2021-2031）：肝炎、ヒト免疫不全ウイルス（HIV）、インフルエンザ、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23MC088 )"坐骨神経痛治療のグローバル市場（2021～2031）：急性坐骨神経痛、慢性坐骨神経痛、その他" (英文：Sciatica Treatment Market By Type (Acute sciatica, Chronic sciatica, Others), By Drug class (Non-steroidal anti-inflammatory drugs, Steroids, Antidepressants, Others), By Distribution channel (Hospital pharmacies, Retail and specialty pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。